December 11, 2015
In the journal Blood, Jean-Jacques Kiladjian and colleagues reported their findings that Pegylated interferon alpha induces hematological and molecular remission in CALR mutated essential thrombocythemia patients. 31 ET patients were followed in the course of this study. The CALR mutant allele burden was reduced from 41% to 26% following treatment, with two patients experiencing complete molecular response. The CALR mutation was not reduced in patients on aspirin and hydroxyurea therapy.
Read the full article here: http://www.bloodjournal.org/content/early/2015/10/20/blood-2015-07-659060?sso-checked=true